The future of biologics design is being reshaped through a groundbreaking collaboration between Novo Nordisk and DTU. By leveraging AI-driven Closed-Loop technology, this partnership aims to automate the discovery and optimization of novel binders—one of the life science industry’s most pressing challenges.
The joint research program brings together expertise from both academia and industry to push the boundaries of biologics development. By integrating closed-loop optimization technology with AI-driven binder design, researchers seek to create a streamlined, automated pipeline that accelerates the development of new binders while minimizing manual intervention.
The initiative builds on recent advancements in protein design, automation, and multi-parameter optimization. With these tools, the program will establish a closed-loop system capable of rapidly designing binders for any target while ensuring they are optimized for developability.
This collaboration is made possible through DTU’s Corporate Partnership model, which fosters long-term strategic cooperation between academic research and industry leaders. By combining Novo Nordisk’s expertise in biologics design with DTU’s cutting-edge research capabilities, the program aspires to drive interdisciplinary innovation in drug discovery. Furthermore, it seeks to develop the next generation of multi-skilled scientists committed to improving the lives of individuals living with chronic conditions.
